Drugs / Trastuzumab
Drug research

Trastuzumab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Herceptin; Herceptin®

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)NCT05002127ALX Oncology Inc.Phase 2, Phase 3Active not recruiting2024-05-24Actual
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926PBYIPhase 2Terminated2023-01-02Actual
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast CancerNCT02492711MacroGenicsPhase 3Completed2021-08-11Actual
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559ALX Oncology Inc.Phase 2Recruiting2027-12Estimated
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804Zai Lab (Shanghai) Co., Ltd.Phase 2Unknown2021-09-03Actual
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerNCT04082364MacroGenicsPhase 2, Phase 3Completed2024-01-15Actual
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerNCT07102381Jazz PharmaceuticalsPhase 2Recruiting2028-01-01Estimated
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersNCT05152147Jazz PharmaceuticalsPhase 3Active not recruiting2026-07-15Actual
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429Jazz PharmaceuticalsPhase 3Recruiting2028-04-28Estimated

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.